Adverum Biotechnologies, Inc. (ADVM) Shares March Higher, Can It Continue?

Zacks Equity Research
Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

As of late, it has definitely been a great time to be an investor in Adverum Biotechnologies, Inc. ADVM. The stock has moved higher by 38% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider ADVM’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as ADVM has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.     

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.  

See the pot trades we're targeting>>                                     


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Adverum Biotechnologies, Inc. (ADVM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research